199 related articles for article (PubMed ID: 12702642)
1. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.
Li Q; Guo Y; Xuan YT; Lowenstein CJ; Stevenson SC; Prabhu SD; Wu WJ; Zhu Y; Bolli R
Circ Res; 2003 Apr; 92(7):741-8. PubMed ID: 12702642
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.
Li Q; Guo Y; Tan W; Ou Q; Wu WJ; Sturza D; Dawn B; Hunt G; Cui C; Bolli R
Circulation; 2007 Oct; 116(14):1577-84. PubMed ID: 17785622
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2.
Wang Y; Kodani E; Wang J; Zhang SX; Takano H; Tang XL; Bolli R
Circ Res; 2004 Jul; 95(1):84-91. PubMed ID: 15166094
[TBL] [Abstract][Full Text] [Related]
4. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning.
Shinmura K; Xuan YT; Tang XL; Kodani E; Han H; Zhu Y; Bolli R
Circ Res; 2002 Mar; 90(5):602-8. PubMed ID: 11909825
[TBL] [Abstract][Full Text] [Related]
5. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.
Dawn B; Xuan YT; Guo Y; Rezazadeh A; Stein AB; Hunt G; Wu WJ; Tan W; Bolli R
Cardiovasc Res; 2004 Oct; 64(1):61-71. PubMed ID: 15364614
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cyclooxygenase-2 upregulation in late preconditioning.
Xuan YT; Guo Y; Zhu Y; Han H; Langenbach R; Dawn B; Bolli R
J Mol Cell Cardiol; 2003 May; 35(5):525-37. PubMed ID: 12738234
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.
Bolli R; Shinmura K; Tang XL; Kodani E; Xuan YT; Guo Y; Dawn B
Cardiovasc Res; 2002 Aug; 55(3):506-19. PubMed ID: 12160947
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.
Bolli R
J Mol Cell Cardiol; 2001 Nov; 33(11):1897-918. PubMed ID: 11708836
[TBL] [Abstract][Full Text] [Related]
9. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene.
Nagayama M; Niwa K; Nagayama T; Ross ME; Iadecola C
J Cereb Blood Flow Metab; 1999 Nov; 19(11):1213-9. PubMed ID: 10566967
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway.
Li Q; Guo Y; Ou Q; Cui C; Wu WJ; Tan W; Zhu X; Lanceta LB; Sanganalmath SK; Dawn B; Shinmura K; Rokosh GD; Wang S; Bolli R
Circulation; 2009 Sep; 120(13):1222-30. PubMed ID: 19752329
[TBL] [Abstract][Full Text] [Related]
11. COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent mechanism.
Jiang X; Shi E; Nakajima Y; Sato S
Life Sci; 2006 Apr; 78(22):2543-9. PubMed ID: 16325209
[TBL] [Abstract][Full Text] [Related]
12. Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.
Li Q; Guo Y; Wu WJ; Ou Q; Zhu X; Tan W; Yuan F; Chen N; Dawn B; Luo L; O'Brien E; Bolli R
Basic Res Cardiol; 2011 Nov; 106(6):1355-66. PubMed ID: 21779912
[TBL] [Abstract][Full Text] [Related]
13. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia.
Nogawa S; Forster C; Zhang F; Nagayama M; Ross ME; Iadecola C
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10966-71. PubMed ID: 9724813
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury.
Birnbaum Y; Ye Y; Rosanio S; Tavackoli S; Hu ZY; Schwarz ER; Uretsky BF
Cardiovasc Res; 2005 Feb; 65(2):345-55. PubMed ID: 15639473
[TBL] [Abstract][Full Text] [Related]
15. Inducible nitric oxide synthase mediates delayed cardioprotection induced by morphine in vivo: evidence from pharmacologic inhibition and gene-knockout mice.
Jiang X; Shi E; Nakajima Y; Sato S
Anesthesiology; 2004 Jul; 101(1):82-8. PubMed ID: 15220775
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.
Li Q; Guo Y; Tan W; Stein AB; Dawn B; Wu WJ; Zhu X; Lu X; Xu X; Siddiqui T; Tiwari S; Bolli R
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H584-9. PubMed ID: 16172153
[TBL] [Abstract][Full Text] [Related]
17. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat.
Patel HH; Hsu AK; Gross GJ
Life Sci; 2004 May; 75(2):129-40. PubMed ID: 15120566
[TBL] [Abstract][Full Text] [Related]
18. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia.
Okamoto H; Ito O; Roman RJ; Hudetz AG
Stroke; 1998 Jun; 29(6):1209-18. PubMed ID: 9626296
[TBL] [Abstract][Full Text] [Related]
19. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase.
Pelletier JP; Fernandes JC; Jovanovic DV; Reboul P; Martel-Pelletier J
J Rheumatol; 2001 Nov; 28(11):2509-19. PubMed ID: 11708426
[TBL] [Abstract][Full Text] [Related]
20. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte.
Wang Y; Guo Y; Zhang SX; Wu WJ; Wang J; Bao W; Bolli R
J Mol Cell Cardiol; 2002 Jan; 34(1):5-15. PubMed ID: 11812160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
